Travere Therapeutics Return on Equity

Travere Therapeutics (TVTX) currently reports a ROE of -270.52%. That is below the Healthcare sector average of 22.76%. Use the charts on this page to explore Travere Therapeutics's ROE history and peer comparisons.

Travere Therapeutics's ROE of -270.52% is lower than the Healthcare sector average of 22.76%. That is roughly 1288.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Travere Therapeutics's current -270.52% should be judged against Healthcare norms (sector average: 22.76%) and against TVTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -270.52%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Travere Therapeutics, and consider following TVTX for alerts when major investors trade the stock.

Travere Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -270.52% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TVTX with unrelated industries.